Evicenter
MarkdownMedical informationP&T meetings
VK2735

Chronic weight management

Last updated
184 sources

Clinical evidence

VENTURE-Oral dosing

57 evidence topics · 12 sources

Objective
Location and study date
Registry study dates
MilestoneRegistry entry
Study start (actual)“2024-12-18”
Primary completion (actual)“2025-06-24”
Study completion (actual)“2025-08-15”
First posted“2025-02-14”
Last update posted“2025-10-06”
Study design
Registry design and masking
Design elementRegistry entry
Allocation“Randomized”
Intervention model“Parallel Assignment”
Masking“Triple”
Primary purpose“Treatment”
Eligibility criteria
Treatment
Study outcomes
Rationale for using percent change in body weight as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants analyzed by arm
ArmEfficacy populationSafety population
Placebo“(n=40)”“(n=40)”
VK2735 15 mg“(n=40)”“(n=40)”
VK2735 30 mg“(n=40)”“(n=40)”
VK2735 60 mg“(n=38)”“(n=40)”
VK2735 90 mg“(n=39)”“(n=40)”
VK2735 120 mg“(n=39)”“(n=40)”
Exploratory maintenance cohort“Efficacy population (n=39)”Not reported
Description of analysis sets
Sample size calculation and multiplicity control

No evidence found.

Estimand and handling of missing data

No evidence found.

Results
Participant disposition
Treatment and study discontinuation by dose
CategoryPlaceboVK2735 15 mgVK2735 30 mgVK2735 60 mgVK2735 90 mgVK2735 120 mg
Participants“(n=40)”“(n=40)”“(n=40)”“(n=40)”“(n=40)”“(n=40)”
Discontinued treatment early, n (%)“7 (18)”“8 (20)”“8 (20)”“11 (28)”“10 (25)”“15 (38)”
TEAE leading to treatment discontinuation, n (%)“5 (13)”“2 (5)”“5 (13)”“7 (18)”“8 (20)”“12 (30)”
Drug-related TEAE leading to treatment discontinuation, n (%)“3 (8)”“1 (3)”“5 (13)”“6 (15)”“8 (20)”“11 (28)”
Discontinued study early, n (%)“2 (5)”“4 (10)”“5 (13)”“5 (13)”“3 (8)”“5 (13)”
TEAE leading to study discontinuation, n (%)“1 (3)”“0”“1 (3)”“0”“1 (3)”“0”
Drug-related TEAE leading to study discontinuation, n (%)“1 (3)”“0”“1 (3)”“0”“1 (3)”“0”
Baseline characteristics
Baseline characteristics by arm, safety population
CharacteristicPlaceboVK2735 15 mgVK2735 30 mgVK2735 60 mgVK2735 90 mgVK2735 120 mg
Participants“(n=40)”“(n=40)”“(n=40)”“(n=40)”“(n=40)”“(n=40)”
Age, mean years“51”“54”“53”“49”“52”“50”
Sex, % male:female“30:70”“20:80”“45:55”“15:85”“32:68”“28:72”
White, %“85”“80”“73”“68”“88”“83”
Non-Hispanic, %“70”“78”“80”“85”“75”“73”
Weight, mean kg“105”“99”“103”“103”“103”“102”
BMI, mean kg/m2“38”“37”“35”“37”“37”“37”
Prediabetes, %“53”“45”“60”“38”“68”“63”
Mean baseline body weight by arm, efficacy population
ArmMean baseline body weight
Placebo“105.2 kg”
VK2735 15 mg“99.0 kg”
VK2735 30 mg“102.9 kg”
VK2735 60 mg“102.8 kg”
VK2735 90 mg“103.4 kg”
VK2735 120 mg“101.9 kg”
Exploratory maintenance cohort“102.8 kg”
Efficacy results
Primary and key secondary endpoints at week 13 by dose
MeasurePlaceboVK2735 15 mgVK2735 30 mgVK2735 60 mgVK2735 90 mgVK2735 120 mg
Participants, efficacy population“(n=40)”“(n=40)”“(n=40)”“(n=38)”“(n=39)”“(n=39)”
Mean change from baseline body weight, least squares mean“-1.3 kg”“-2.2 kg”“-7.1 kg”“-8.8 kg”“-11.5 kg”“-12.1 kg”
Mean percent change from baseline, least squares mean“-1.3 %”“-2.3 %”“-7.0 %”“-8.7 %”“-11.1 %”“-12.2 %”
p-value versus baseline“-”“0.0057”“<0.0001”“<0.0001”“<0.0001”“<0.0001”
Placebo-adjusted mean percent change from baseline“-”“-1.0 %”“-5.7 %”“-7.4 %”“-9.8 %”“-10.9 %”
p-value versus placebo, percent change“-”“-”“<0.0001”“<0.0001”“<0.0001”“<0.0001”
Percent reporting at least 10% weight loss“5 %”“8 %”“35 %”“40 %”“59 %”“80 %”
p-value versus placebo, at least 10% weight loss“-”“-”“<0.01”“0.0017”“< 0.0001”“<0.0001”
Weight change at week 16, three weeks after the last dose
ArmWeek 16 change from baseline, least squares mean
Placebo“-1.4%”
VK2735 30 mg“-6.7%”
VK2735 30/60 mg (60 mg arm)“-8.2%”
VK2735 30/60/90 mg (90 mg arm)“-10.3%”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Treatment-emergent adverse events by dose
CategoryPlaceboVK2735 15 mgVK2735 30 mgVK2735 60 mgVK2735 90 mgVK2735 120 mg
Participants“(n=40)”“(n=40)”“(n=40)”“(n=40)”“(n=40)”“(n=40)”
TEAEs, n (%)“34 (85)”“35 (88)”“33 (83)”“33 (83)”“37 (93)”“36 (90)”
Treatment-related TEAEs, n (%)“27 (68)”“28 (70)”“30 (75)”“31 (78)”“37 (93)”“34 (85)”
Common drug-related gastrointestinal adverse events by dose
Drug-related gastrointestinal adverse events by severity grade
SeverityPlaceboVK2735 15 mgVK2735 30 mgVK2735 60 mgVK2735 90 mgVK2735 120 mg
Any drug-related GI TEAE, mild, grade 1, n (%)“17 (43)”“18 (45)”“16 (40)”“18 (45)”“21 (53)”“18 (45)”
Any drug-related GI TEAE, moderate, grade 2, n (%)“6 (15)”“6 (15)”“11 (28)”“12 (30)”“13 (33)”“11 (28)”
Any drug-related GI TEAE, severe, grade 3, n (%)“1 (3)”“0”“0”“0”“0”“2 (5)”
Nausea, mild/moderate/severe, % of participants“40/8/0”“30/5/0”“38/18/0”“33/20/0”“55/18/0”“38/18/5”
Constipation, mild/moderate/severe, % of participants“13/10/0”“13/10/0”“10/10/0”“20/10/0”“33/10/0”“25/3/0”
Vomiting, mild/moderate/severe, % of participants“3/8/0”“5/0/0”“8/8/0”“18/3/0”“30/5/0”“15/15/5”
Diarrhea, mild/moderate/severe, % of participants“10/0/3”“5/0/0”“8/0/0”“15/0/0”“10/5/0”“15/10/0”
Laboratory values, vital signs, and heart rate

No evidence found.

Study limitations
Summary: limitations of the VENTURE-Oral Dosing evidence

Treatment lasted 13 weeks, and about 40 participants were randomized to each of 7 arms (280 in total). The release reports that weight loss showed “no plateau” at 13 weeks, so the maximal effect of each dose is not known from these data; FDA draft guidance asks that phase 2 duration capture “maximal or near-maximal” effects and sets its efficacy benchmark after 1 year of treatment. Week 16 off-treatment values were reported only for placebo and the 30, 60, and 90 mg arms.

Results are available only in company press releases, a sponsor-funded congress poster, a corporate presentation, and investor call transcripts. No peer-reviewed publication was identified, and the registry record has no posted results. Pharmacokinetic results, a stated objective, have not been reported. No document describes the sample size calculation, control of multiplicity, the estimand, or the handling of missing data.

Treatment discontinuation was 18% with placebo and ranged from 20% (15 mg and 30 mg) to 38% (120 mg) across the fixed-dose arms; discontinuation of treatment due to a TEAE was 13% with placebo and 30% with 120 mg. The release describes discontinuation due to adverse events as “low and well-balanced”. Its pooled VK2735 rates (28% for any treatment discontinuation and 20% for discontinuation due to an adverse event) are higher than the totals of the 5 fixed-dose arms in the per-arm tables (52 of 200, 26%, and 34 of 200, 17%); no document states whether the pooled rates include the exploratory maintenance cohort, whose disposition and adverse events are reported only as qualitative statements on the investor call. Efficacy was analyzed in a modified population that required a post-baseline weight, with 38 or 39 participants in the 60, 90, and 120 mg arms.

The fixed-dose arms were titrated in 2-week steps starting at 30 mg, every participant took 4 tablets daily after an overnight fast, and no food-effect study had been done. The doses later chosen for the phase 3 SUNRISE trials (27.5, 35, and 55 mg) were not tested as fixed arms. Nausea was reported by 48% of placebo recipients, and the company noted on its investor call that placebo adverse event rates were higher than in the earlier study. Participants with diabetes were excluded, all 15 sites were in the United States, and most participants were White, non-Hispanic, and female.

The documents differ on some points. The ECO release names the poster's trial the “VENTURE-2 Study” and calls the study “Phase 2a”. A corporate presentation note states “Baseline BMI ≥30 in all subjects” although eligibility allowed a BMI of 27 kg/m2 or higher with a comorbidity. The poster footnote on serious adverse events states “Three participants” and then lists one participant in the 60 mg arm and “1 pt with dehydration and 2 pts with nausea/vomiting” in the 120 mg arm. A third-party transcript of a November 2025 presentation records the maintenance cohort ending at 8.2% weight loss, while the release reports 9.2%. The registry arms are labeled “Dose #1” to “Dose #6” without the doses.